Potential for Abuse of Hydrocodone Combination Products

Published Online: Monday, January 13, 2014
Follow Pharmacy_Times:
In this video, Mary Lynn McPherson, PharmD, professor and vice chair at the University of Maryland School of Pharmacy, discusses the appeal of hydrocodone combination products to drug abusers.
 
This is the third in a series of videos in which Dr. McPherson argues in favor of categorizing hydrocodone combination products as Schedule II drugs, and Jeff Fudin, PharmD, argues against doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Used alongside antidepressants, OTC analgesics and anti-inflammatories purchased from pharmacies may effectively treat patients with depression without increasing their risk of adverse events.
The transdermal buprenorphine manufacturer has launched an awareness campaign to address specific knowledge gaps among pharmacists that pertain to opioids.
Although pharmacies can legally dispense remaining refills of prescriptions for rescheduled hydrocodone combination products submitted prior to October 6, 2014, over the next 6 months, many drug chains have chosen not to honor those refills.
Patients with irritable bowel syndrome cannot block pain signals from the gut as easily as those without the gastrointestinal condition.
Latest Issues
$auto_registration$